ATXN3 and cervical carcinoma: These findings establish ATXN3 as a central mediator of hypoxia-induced malignancy in a subtype-specific manner, and demonstrate that targeted manipulation of ATXN3 expression can reverse hypoxic effects across cervical cancer subtypes.